title: [Changes of serum interferon-gamma levels in mice bearing S-180 tumor and the interventional effect of immunomodulators].
abstract: OBJECTIVE
  To investigate the changes of serum inteferon-gamma (IFN-gamma) in mice bearing S-180 tumor and explore the role of the endogenous IFN-gamma in confining the transplanted tumor by intervention with immunomodulators.
  
  
  METHODS
  Mouse models bearing S-180 solid tumor were established and subjected to intragastric administration of Ganoderma lucidum polysaccharides (GLP) or cyclosporine A (CsA) at different daily doses for 9 consecutive days. Serum IFN-gamma levels were measured in untreated tumor-bearing mice and in those after completion of GLP or CsA treatments by enzyme-linked immunosorbent assay (ELISA), and the changes of the tumor weight in the treated mice were evaluated.
  
  
  RESULTS
  It was found for the first time that serum IFN-gamma levels in the tumor-bearing mice increased progressively within the initial 20 days after tumor implantation. The serum IFN-gamma levels in the 3 GLP-treated groups (at daily doses of 400, 200, and 100 mg/kg) all increased, which was the most obvious in 400 mg/kg GLP-treated group, and the tumor weight decreased significantly in response to GLP treatment, but the most conspicuous effect occurred with the daily dose of 200 mg/kg, and no significant statistical correlation was found between the two parameters. CsA treatment (at 20, 10, and 5 mg/kg, respectively) resulted in reduced serum IFN-gamma levels but produced virtually no effect on the tumor weight, and no obvious correlation was found between serum IFN-gamma level and the tumor weight.
  
  
  CONCLUSIONS
  Increased serum IFN-gamma levels following GLP treatment are not significantly correlated to tumor growth inhibition in mice, and CsA reduces serum IFN-gamma levels without affecting the tumor weight, suggesting that endogenous IFN-gamma is not a major immunomodulating factor in growth inhibition of transplanted S-180 tumor.
authors.affiliation: Institute of Pharmaceutical Sciences, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China. lilybear@fimmu.com
authors.forename: Li
authors.initials: L
authors.lastname: Li
authors.forename: Lin-Sheng
authors.initials: LS
authors.lastname: Lei
authors.forename: Chuan-Lin
authors.initials: CL
authors.lastname: Yu
mesh_terms: D000818:Animals; D016572:Cyclosporine / Q000494:pharmacology; D005260:Female; D032902:Ganoderma / Q000737:chemistry; D007155:Immunologic Factors / Q000494:pharmacology*; D007371:Interferon-gamma / Q000097:blood*; D008297:Male; D051379:Mice; D011134:Polysaccharides / Q000494:pharmacology; D012510:Sarcoma 180 / Q000097:blood* / Q000473:pathology / Q000517:prevention & control*; D047368:Tumor Burden / Q000187:drug effects
chemical_list: D007155:Immunologic Factors; D011134:Polysaccharides; D007371:Interferon-gamma; D016572:Cyclosporine